Table 1.
Demographic and disease characteristics of the patients at study inclusion
| Characteristic | PPI users, n = 43 (43.4%) | PPI nonusers, n = 56 (56.6%) | p value |
|---|---|---|---|
| Age, median (range), yr | 62 (30–78) | 58 (22–78) | .377 |
| Male gender, n (%) | 26 (60.5) | 41 (73.2) | .179 |
| Histology, n (%) | .105 | ||
| Clear cell RCC | 36 (83.7) | 39 (69.6) | |
| Nonclear cell RCC, n (%) | 7 (16.3) | 17 (30.4) | |
| IMDC risk groups, n (%) | .507 | ||
| Good risk | 6 (13.9) | 13 (23.2) | |
| Intermediate risk | 28 (65.1) | 33 (58.9) | |
| Poor risk | 9(20.9) | 10 (17.8) | |
| Previous nephrectomy, n (%) | 35 (81.4) | 47 (83.9) | .740 |
| Cabozantinib line of treatment, n (%) | .130 | ||
| First and second line | 10 (23.3) | 21 (37.5) | |
| Third line and beyond | 33 (76.7) | 35 (62.5) |
Abbreviations: IMDC, International Metastatic RCC Database Consortium; PPI, proton pump users; RCC, renal cell carcinoma.